Inozyme Pharma (INZY) Competitors

AbCellera Biologics (NASDAQ:ABCL) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Which has higher earnings and valuation, ABCL or INZY?

Inozyme Pharma has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$28.83M	37.37	-$162.86M	-$0.56	-6.45
Inozyme Pharma	N/A	N/A	-$102.02M	-$1.69	-2.36

Does the media prefer ABCL or INZY?

In the previous week, AbCellera Biologics had 2 more articles in the media than Inozyme Pharma. MarketBeat recorded 4 mentions for AbCellera Biologics and 2 mentions for Inozyme Pharma. AbCellera Biologics' average media sentiment score of 0.64 beat Inozyme Pharma's score of 0.63 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inozyme Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend ABCL or INZY?

AbCellera Biologics presently has a consensus price target of $8.33, suggesting a potential upside of 130.84%. Inozyme Pharma has a consensus price target of $11.75, suggesting a potential upside of 194.49%. Given Inozyme Pharma's higher possible upside, analysts clearly believe Inozyme Pharma is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Inozyme Pharma	0 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.44

Is ABCL or INZY more profitable?

Inozyme Pharma has a net margin of 0.00% compared to AbCellera Biologics' net margin of -737.56%. AbCellera Biologics' return on equity of -15.98% beat Inozyme Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-737.56%	-15.98%	-12.38%
Inozyme Pharma	N/A	-159.93%	-82.48%

Which has more volatility & risk, ABCL or INZY?

AbCellera Biologics has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500.

Do institutionals & insiders hold more shares of ABCL or INZY?

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are held by institutional investors. 28.9% of AbCellera Biologics shares are held by insiders. Comparatively, 12.2% of Inozyme Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

AbCellera Biologics beats Inozyme Pharma on 8 of the 14 factors compared between the two stocks.